Innovative simvastatin-loaded emulgel effectively treats vulvovaginal candidiasis: in vivo efficacy and in vitro biopharmaceutical analysis
Authors:
- Maria Eliza Samuel AmorimMAMaria Eliza Samuel Amorim
- Natália de Oliveira Lima RibeiroNRNatália de Oliveira Lima Ribeiro
- Flávia Carmo Horta PintoFPFlávia Carmo Horta Pinto
- Pedro Ferreira de OliveiraPOPedro Ferreira de Oliveira
- Marcus Vinícius PomminiMPMarcus Vinícius Pommini
- Mateus Boaventura SiqueiraMSMateus Boaventura Siqueira
- Zakariyya Muhammad BelloZBZakariyya Muhammad Bello
- Rodrigo Luiz FabriRFRodrigo Luiz Fabri
- Marcelo Gonzaga de FreitasMFMarcelo Gonzaga de Freitas
- Renê Oliveira Do CoutoRCRenê Oliveira Do Couto
- 18 August 2025
- journal article
- research article
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 56 (4) , 2687-2702
Abstract
We evaluated the pre-clinical efficacy of simvastatin (SVT)-loaded emulgels in an in vivo model of azole-resistant Candida albicans (ATCC 10231)-induced vaginal candidiasis and conducted in vitro biopharmaceutical characterization of the most effective formulation. The efficacy of SVT-loaded emulgels (15, 30, and 60 mg/g) was assessed in immunosuppressed Wistar rats with induced candidiasis and compared to commercially available vaginal creams containing clotrimazole (10 mg/g) or nystatin (25,000 IU/g). Products were administered once daily for seven days (n = 5 per group). A high-resolution and sensitive HPLC-PDA method was developed and validated to quantify SVT, determine its solubility in the release medium, and evaluate its in vitro release profile and kinetics. The 60 mg/g SVT-loaded emulgel achieved a 100% reduction in fungal load after 7 days (p < 0.05). SVT solubility in the release medium was 881 ± 36 µg/mL, and its content in the emulgel was 114.95 ± 4.46% m/m. The controlled release kinetics followed Makoid-Banakar’s model, indicating an average release rate of 0.036%/h. Therefore, the 60 mg/g SVT-loaded emulgel shows potential as a therapeutic strategy for treating resistant vulvovaginal candidiasis, warranting further clinical studies.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (25203)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001, 88881.709052/2022-01)
This publication has 62 references indexed in Scilit:
- Repurposing simvastatin in cancer treatment: an updated review on pharmacological and nanotechnological aspectsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- In vitro and ex vivo models for evaluating vaginal drug delivery systemsAdvanced Drug Delivery Reviews, 2022
- Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK BiobankEndocrinology, Diabetes & Metabolism, 2022
- Simvastatin accelerates the healing process of burn wound in Wistar rats through Akt/mTOR signaling pathwayAnnals of Anatomy - Anatomischer Anzeiger, 2021
- Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver InjuryDigestive Diseases and Sciences, 2020
- A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participantsDrug Delivery and Translational Research, 2020
- Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor PathwaysClinical Reviews in Allergy & Immunology, 2020
- Are the Statins promising antifungal agents against invasive candidiasis?Biomedicine & Pharmacotherapy, 2019
- Topical Simvastatin Accelerates Wound Healing in Diabetes by Enhancing Angiogenesis and LymphangiogenesisThe American Journal of Pathology, 2012
- A New Model of Vaginal Infection by Candida albicans in RatsMycopathologia, 2010